Search

Displaying results 5601 - 5610 of 10000 in total
  1. Drug

    Uldazepam

    go.drugbank.com/drugs/DB21290
    Experimental

    Uldazepam is a small molecule drug. The usage of the INN stem '-azepam' in the name indicates that Uldazepam is a diazepam derivative. Uldazepam has a monoisotopic molecular weight of 359.06 Da.

  2. Drug

    Fluradoline

    go.drugbank.com/drugs/DB21333
    Experimental

    Fluradoline is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Fluradoline is a analgesic. Fluradoline has a monoisotopic molecular weight of 301.09 Da.

  3. Drug

    Pinoxepin

    go.drugbank.com/drugs/DB21397
    Experimental

    Pinoxepin is a small molecule drug. The usage of the INN stem '-oxepin' in the name indicates that Pinoxepin is a tricyclic compound. Pinoxepin has a monoisotopic molecular weight of 398.18 Da.

  4. Drug

    Ruzadolane

    go.drugbank.com/drugs/DB21444
    Experimental

    Ruzadolane is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Ruzadolane is a analgesic. Ruzadolane has a monoisotopic molecular weight of 375.13 Da.

  5. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  6. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  7. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  8. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

  9. Drug

    Bromopride

    go.drugbank.com/drugs/DB09018
    Investigational

    Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.

    Synonyms: 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
  10. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).